Protagonist Therapeutics
PTGX
PTGX
185 hedge funds and large institutions have $1.73B invested in Protagonist Therapeutics in 2024 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 61 increasing their positions, 57 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
7% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 57
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
83% less call options, than puts
Call options by funds: $1.14M | Put options by funds: $6.85M
Holders
185
Holding in Top 10
6
Calls
$1.14M
Puts
$6.85M
Top Buyers
| 1 | +$45.1M | |
| 2 | +$27M | |
| 3 | +$26.8M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$24.1M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$18.4M |
Top Sellers
| 1 | -$57.5M | |
| 2 | -$40.9M | |
| 3 | -$24.9M | |
| 4 |
Morgan Stanley
New York
|
-$14.6M |
| 5 |
SC
Stempoint Capital
New York
|
-$11.8M |